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Summary.-The effect of adjuvant immunotherapy with a single neighbourhood
injection of 2 mg C. parvum (CP) was investigated in a randomized study involving
43 patients with carcinoma of the cervix uteri, all of whom were treated by radical
surgery.. All patients had carcinoma confined to the cervix, the upper part of the
vagina or the parametrial region. When the malignancy had spread to the para-
metrial region, additional postoperative radiotherapy was given. 22 patients received
immunotherapy 10 days before surgery, whereas the remaining 21 control patients
received no immune stimulation. Only minor side effects of CP were encountered.
Follow-up shows a relapse rate of 5% in the CP treated group and of 29% in the
controls (P<0-05). A further 15 patients with more advanced malignancies were
added to our studies. In these, CP stimulation had no effect on relapse rates, but the
relapse-free intervals were longer after immune stimulation: control 3-5 months
(mean) ± 1-5 (s.d.), CP 13-0 months +7-0 (P<0-05).
The number of peripheral T cells and the ability to become sensitized to DNCB
were increased after CP stimulation. A decrease was found in the number of blood
monocytes and the number of monocytes capable of transforming into active macro-
phages, indicating a possible sequestration of these cells in the tissues.
THE importance of immunological reac-
tions, especially those involving T lympho-
cytes and macrophages in the in vivo
destruction of tumour cells has been
demonstrated (Woodruff, 1980). This
ability ofthe immune system is ofparticu-
lar interest, since patients suffering from a
malignancy show impaired immune reac-
tions. Decreased mitogenic responses (De
Cast et al., 1975; Wanebo et al., 1980),
decreased dinitrochlorobenzene (DNCB)
skin tests (Pinsky et al., 1974; Elhilali,
1978), fewer T cells (Wybran & Fudenberg,
1973) and impaired monocyte chemotactic
response (Boetcher & Leonard, 1974;
Hausman et al., 1975) have all been re-
ported in patients with advanced malig-
nant disease. Factors of low molecular
weight derived from the tumour are
involved in these functional disturbances
(Snijderman et al., 1980).
Corynebacterium parvum (CP) is known
to be a potent stimulator of the immune
system, and both beneficial (Israel &
Edelstein, 1975; Minton et al., 1976;
Millar et al., 1981) and detrimental effects
(von Blomberg et al., 1980) of its use in
cancer patients have been reported. Im-
mune stimulation is known to be particu-
larly effective against small numbers of
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tumour cells (Milas et al., 1976). Therefore
the effect of CP might be optimal when
used as an adjuvant to radical surgery. It
could then interfere with the growth of
remote, dormant cancer cells (Woodruff,
1961) or cells metastasizing during the
operation (Roberts et al., 1961; Griffith et
al., 1973). Animal experiments have
shown beneficial effects of presurgical
regional immune therapy in murine
lymphosarcoma (Mathe, 1978).
This report deals with the clinical and
immunological effects of a single neigh-
bourhood injection of 2 mg of CP 10 days
before radical surgical removal of a cervix
carcinoma. Preliminary results show bene-
ficial effects on relapse rates and relapse-
free intervals. Enhanced T-cell function
could underlie this phenomenon.
PATIENTS AND METHODS
Fifty-eight patients suffering from squam-
ous-cell carcinoma of the uterine cervix
preoperatively staged according to the
F.I.G.O. classifications as I and II were
studied. The mean age was 49 years + 11
(s.d.). All patients were randomly allocated to
2 treatment groups using a computer-
generated pseudo-random table, in such a
way that an identical distribution of age and
preoperative clinical stage were obtained.
One of these groups, including 29 patients,
received immunotherapy 10 days before
radical hysterectomy and lymphadenectomy
whereas the other received surgery only. 56
of the 58 hysterectomies were performed by
one and the same surgeon (J.G.S.). It was
found that 15 patients had more advanced
malignancies at operation, with involvement
ofthe pelvic lymph nodes, the pelvic wall, the
lower part of the vagina, the urine bladder,
the rectum or other distant metastases. But,
for our study, we concentrated mainly on the
remaining 43 patients whose malignancies at
operation were confined to the cervix, the
upper part of the vagina and the parametrial
region.
Direct postoperative radiotherapy was
given when the malignancy affected the para-
metrial region, the pelvic lymph nodes, the
pelvic wall or had grown beyond those stages.
Patients entering the trial had not received
any treatment before or had any contraindi-
cations for CP treatment.* They were given
a clinical follow-up examination every 6
weeks for 6 months, and later every 3
months. Relapse was defined as clinical evi-
dence of local or distant recurrent malignant
disease of patients with operable carcinoma.
In the group of 15 patients with disseminated
disease, relapse w!as defined as a rehospitaliza-
tion for further treatment of overt malignant
disease.
Immunotherapy. Four neighbourhood in-
jections of CP were given 10 days before
operation at 4 sites closely surrounding the
tumour. The Wellcome strain of CP CN 6134
(Burroughs Wellcome Batch No. Bb 3995)
w-as used. A total of 2 mg CP suspended in
2 ml of physiological saline was injected.
Lymphocyte and monocyte count.-The abso-
lute number of lymphocytes and monocytes/
litre blood was calculated from differential
blood smears and the absolute number of
leucocytes/l blood.
Isolation of blood mononuclear cells.-Blood
mononuclear cells were isolated on a Ficoll-
Isopaque gradient (Boyum, 1968) using
freshly drawn defibrinated blood collected
3 days before CP administration and a few
hours before the operation (10 days after
immunotherapy).
E and EAC rosettes-.The percentages of E
and EAC rosetting cells were estimated in the
mononuclear cell suspension by the method
described by Zeilemaker et al. (1974). The
absolute numbers were calculated by multi-
plication from the total peripheral lympho-
cyte count.
Monocytes tran.sforming into adherent macro-
phages. The percentage of monocytes trans-
forming into adherent macrophages was
measured according to the method described
by Currie & Hedley (1977): 2 x 105 of the
Ficoll-Isopaque isolated mononuclear cells
were incubated in 0-1 ml RPMI 1640 enriched
with 5000 autologous serum in Titertee wells
(Flow Laboratories Microtitration Multiwell
plate CAT No. 7621205). The number of
monocytes in these cell suspensions had been
estimated by a-naphthyl butyrate esterase
stain (Mullink et al., 1979). After 7 days in
culture the supernatants were discarded from
the wells and the nonadherent cells washed
out with culture medium. Thereafter, the
* Information For Investigators C. Parvum, Wellcome (c/o Department of Clinical Immunology and
Chemotherapy, Wellcome Research Laboratories, Beckenham, Kent).
8578M. H. MIGNOT ET AL.
adherent macrophages were detached, and
their nuclei stained with a solution of 1: 2000
crystal violet and 0 IM citric acid.
The percentage of the monocytes trans-
formed into adherent macrophages was
calculated from the number of monocytes put
into the wells and the number of adherent
cells found after 7 days' culture.
Anti-CP antibodies.-These were estimated
by ELISA, as described by Engvall &
Perlmann (1972).
DNCB skin test.-Contact sensitivity to
dinitrochlorobenzene (DNCB, Janssen
Beersse, Belgium) was induced by epi-
cutaneous application on the hip of 2 mg
DCNB in 01 ml acetone 3 days before the
intracervical CP injection.
A challenge with 10 ,tg DNCB in acetone
was carried out 6 days after immune stimu-
lation. The response was evaluated after 48 h
and classified as: -= no reaction; + =
erythema; + + =erythema and induration;
+ + + =erythema, induration and vesicu-
lation.
Statistical analysis.-The comparability of
the immune therapy and the control group
was calculated by Wilcoxon's 2-sample test
and the Fisher's 2 x 2 exact test.
RESULTS
The clinical behaviour of the patients in
a follow-up study ranging from 7 months
to 4 years is given in Figs 1 and 2. Fewer
showed relapses after CP treatment among
the 43 patients with carcinomas confined
to the cervix, the upper part of the vagina
or the parametrial region (CP group 500;
control group 29%o Fisher's exact test
P < 0.05). The relapse rate in our control
group is of the order of that reported for
radical surgery (de Bruine, 1954; Plentl &
Friedman, 1971), viz. 20-25%.
When this is combined with pre- or
postoperative radiotherapy the relapse
rates are lowered to 10-20% (de Graaff,
1980). In our clinic, recurrent disease is
treated with radiotherapy, which has
proved to be as effective as direct pre- or
postoperative radiotherapy.
In the group with disseminated disease
(Fig. 2) the relapse rates were not influ-
enced by the neighbourhood injection of
CP, but the relapse-free intervals were
significantly longer (13 0 + 7 0 months vs
3-5 + 1P5 months, Wilcoxon test, P < 0.05).
Figs 1 and 2 also show that this tendency
for delayed recurrence was apparent in all
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FIG. 1. The clinical follow up of 43 patients
with operable carcinoma of the uterine
cervix, 22 of whom were treated with CP.
Carcinomas were confined to the cervix, the
upper part ofthe vaginaand the parametrial
region. Patients with carcinomas affecting
the parametrial region were postoperatively
treated with radiotherapy, indicated by
"R". * =relapse, which wastreatedbyradio-
therapy when it occurred; + =death. A
statistically significant smaller relapse rate
(Fisher 2 x 2 exact test, P < 0 05) was
found in the CP-treated group after one
year's follow-up.
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FIG. 2. The clinical follow-up of 15 patients
with disseminated carcinoma of the
uterine cervix, including carcinomas affect-
ing the pelvic wall, the lower part of the
vagina, the pelvic lymph nodes with distant
metastases. 7 of the patients were treated
with CP. All were radically operated and
received additional postoperative radio-
therapy. * =relapse, which was healed
by radiotherapy, + = death. A significantly
longer relapse-free interval (Wilcoxon test,
P < 005) was found in the CP treated
group.
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FIG. 3. The ntumber of E and EAC rosetting cells per litre blood at the time of operation, 10 days after
immune stimulation (P < 0-05, Wilcoxon test).
patients treated with CP, whether they
had localized or disseminated disease (CP
group: 13-0 + 641 vs control group: 6-5 + 3-9
months, Wilcoxon test P< 0 05).
Only minor side effects were encountered
after the neighbourhood injection of 2 mg
of CP. All patients experienced feelings of
discomfort, and 85% had a febrile response
of up to 39TC. This reaction subsided
within 24-36 h. Nausea, vomiting and
other severe reactions described after i.v.
administration ofCP were not observed.
Fig. 3 shows the number of E and EAC
rosetting cells at the time of operation.
Significantly more E rosettes were found
in the immunotherapy group than in the
controls; the latter being equal to healthy
individuals of matched age and sex. EAC
rosettes measured at the same time were
similar in all groups of patients and
healthy individuals.
The DNCB skin test gave another indi-
cation of improved T-cell function after
CP treatment (Fig. 4). More intense
delayed reactions to 10 Hg DNCB were
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FIG. 4. The skin reactivity to 10 ,ug DNCB
9 days after a 2mg primary sensitization.
Immune stimulation had been given 6 days
earlier. The test was read at 48 h. - =no
reaction; + =erythema; + + =erythema
and induration; + + + =erythema, in-
duration and vesiculation (P < 0 05,
Fisher's exact test).
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FIG. 5.-The number of monocytes per litre
bloodi before any therapy was given. A com-
parison is made between the cervix-
carcinoma patients and healthy individuals
ofmatched age and sex (P < 0-05, WilcoxoIn
test).
seen. Specific B-cell stimulation did not
occur, as the titre of CP antibodies was
unchanged in serum samples taken 10
days after local stimulation.
Before therapy the number of blood
monocytes was decreased in carcinoma of
cervix patients (Fig. 5), but the number
of macrophage precursors (cells capable of
maturing into macrophages) was slightly
raised, though this did not reach statistical
significance (Wilcoxon test, P= 010).
After CP treatment the number ofperiph-
eral monocytes dropped significantly to
even lower values, as did macrophage pre-
cursors. No changes were found in the
control group.
DISCUSSION
Our preliminary findings indicate that
a relatively small dose of CP given in the
neighbourhood of a cervix carcinoma 10
days before radical surgery might slow
down the growth of dormant or meta-
stasized cancer cells left behind at opera-
tion. A lower relapse rate was observed in
patients with localized disease, whereas in
more advanced disease a longer relapse-
free interval was achieved. A recent study
on carcinomas of the oral cavity, pharynx
and larynx also indicated that neighbour-
hood stimulation with CP in addition to
surgical treatment decreased the recur-
rence rates in operable disease (Terz &
Kaplan, 1980). Several other clinical trials
are in progress, involving malignant
melanoma, bronchus (Ludwig Lung Can-
cer Group, 1978) and gastric carcinoma
(Dykes & Trejdosiewicz, 1978) but no
information is yet available on subsequent
follow-up. Combinations of surgery with
immune stimulants other than CP, such
as BCG (Bier et al., 1980; Jansen et al.,
1980), poly A-poly U (Lacour et al., 1980)
and interferon (Ikic et al., 1981a,b,c) have
also given beneficial results.
CP is known to stimulate local inter-
feron production by lymphocytes, prob-
ably NK cells (Kirchner et al., 1.979). The
T-cell responsiveness, as measured by the
number of E rosettes and the D.H.
reactivity to DCNB were raised in the
CP treated group, including both localized
and disseminated diseases. This enhanced
T-cell responsiveness at the time of opera-
tion might counteract the transient T-cell
suppression known to occur due to surgical
trauma and anaesthetics (Tarpley et al.,
1977). The effects on T lymphocytes are
probably induced via stimulation of the
monocyte/macrophage series (Scott, 1972).
In an animal study on lymph-node
histological response after local CP stimu-
lation, interactions between lymphocytes
and macrophages were evident; 4 to 8
days after stimulation both lymphoblast
transformation and mitotic activity were
present in the near vicinity of stimulated
interdigitating cells, the antigen-handling
macrophages of the paracortex (Mignot et
et., submitted). From these observations
it is likely that the interval between CP
injection and operation should not be less
than 6-8 days.
In our group of patients the number of
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peripheral monocytes dropped after im-
munotherapy. The percentage of these
cells capable of transforming into active
macrophages also declined. This disappear-
ance of cells from the blood is known to
appear after CP treatment (Thatcher et al.,
1979) and lasts for several days. It might
indicate sequestration of active cells in
other tissue compartments. Histological
studies are in progress to see whether
there are more macrophages round the
tumour at operation.
The clinical and immunological data of
this trial on cervix carcinoma are in sharp
contrast to those of a clinical trial re-
ported on an earlier occasion, involving
patients with advanced carcinoma of the
bronchus (von Blomberg et al., 1980). In
these patients, CP was administered i.v.
in a dose of 7.5 mg/yn2. Severe side effects
were encountered, and those treated with
CP appeared to have significantly shorter
survival. No T-cell stimulation was found,
but the titre of CP antibodies was raised.
Such a rise of specific antibodies was not
found in cervix-carcinoma patients. Pos-
sibly a large systemic dose of CP stimu-
lates B cells rather than T cells and, by
interference, the production of tumour-
enhancing antibodies (Moller, 1963).
Extension of local CP treatment is
indicated, and clinical trials are now being
carried out involving the combination of
paralesional CP and radical surgery of
carcinomas of the bronchus, oropharynx
and the uterine cervix.
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